Cybin Inc (AMEX:CYBN) shares traded 11.10% higher at $0.49 on Wall Street last session.
In accordance with the data, 4 analysts cover Cybin Inc (AMEX:CYBN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $3.00, we find $4.50. Given the previous closing price of $0.44, this indicates a potential upside of 922.73 percent. CYBN stock price is now 12.35% away from the 50-day moving average and 24.80% away from the 200-day moving average. The market capitalization of the company currently stands at $117.45M.
It has been rated a hold by 0 analysts and a buy by 4. Brokers who have rated the stock have averaged $5.50 as their price target over the next twelve months.
A total of 15.71% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYBN stock. A new stake in Cybin Inc shares was purchased by INTEROCEAN CAPITAL GROUP, LLC during the first quarter worth $49,000. CONNECTICUT WEALTH MANAGEMENT, LLC invested $26,000 in shares of CYBN during the first quarter. In the first quarter, THRIVE WEALTH MANAGEMENT, LLC acquired a new stake in Cybin Inc valued at approximately $26,000. LPL FINANCIAL LLC acquired a new stake in CYBN for approximately $14,000. LEGACY FINANCIAL GROUP LLC purchased a new stake in CYBN valued at around $11,000 in the second quarter. In total, there are 72 active investors with 11.03% ownership of the company’s stock.
Cybin Inc (AMEX: CYBN) opened at $0.4600 on Wednesday. During the past 12 months, Cybin Inc has had a low of $0.21 and a high of $0.71. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.61, and a quick ratio of 2.61. The fifty day moving average price for CYBN is $0.4389 and a two-hundred day moving average price translates $0.3922 for the stock.
The latest earnings results from Cybin Inc (AMEX: CYBN) was released for Jun, 2023.
Cybin Inc(CYBN) Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
